Digoxin: Na⁺/K⁺ ATPase Pump Inhibitor for Cardiac & Antiviral Research

Executive Summary: Digoxin is a cardiac glycoside that inhibits the Na⁺/K⁺-ATPase pump, enhancing cardiac contractility and serving as a key reference in heart failure and arrhythmia research (APExBIO). It demonstrates dose-dependent antiviral activity against chikungunya virus (CHIKV) in human and animal cell lines at 0.01–10 μM concentrations (source). Digoxin is insoluble in water and ethanol but dissolves at ≥33.25 mg/mL in DMSO, and is supplied as a solid with >98.6% purity. Animal models, including canine congestive heart failure, show intravenous Digoxin (1–1.2 mg) increases cardiac output and reduces right atrial pressure. The product is provided by APExBIO with full QC documentation (HPLC, NMR, MSDS).

Biological Rationale

Digoxin has a long-established role in cardiovascular disease research. It is classified as a cardiac glycoside and acts primarily by inhibiting the Na⁺/K⁺-ATPase enzyme, a critical membrane pump in cardiomyocytes (related article). The resulting increase in intracellular sodium indirectly promotes calcium influx via the Na⁺/Ca²⁺ exchanger, thereby amplifying myocardial contractility. This mechanism underpins its use in heart failure and arrhythmia models. In recent years, Digoxin has also emerged as a tool for antiviral studies, notably for its efficacy in inhibiting chikungunya virus infection in both immortalized and primary human cell lines. This article extends previous reviews by providing new data on experimental solubility, purity, and translational workflows for bench-to-bedside applications.

Mechanism of Action of Digoxin

Digoxin binds specifically to the extracellular alpha-subunit of the Na⁺/K⁺-ATPase pump, leading to competitive inhibition of ATP hydrolysis. This action impedes the active transport of sodium and potassium ions across the plasma membrane. Increased intracellular sodium reduces the activity of the Na⁺/Ca²⁺ exchanger, resulting in calcium accumulation within cardiomyocytes. Elevated calcium enhances excitation-contraction coupling and increases the force of cardiac contractions. In the context of antiviral research, Digoxin disrupts host cell ion homeostasis, impairing the replication cycle of certain viruses, including CHIKV. The compound’s specificity for the Na⁺/K⁺-ATPase pathway makes it an informative pharmacological probe for both signaling and functional studies (see more).

Evidence & Benchmarks

• Digoxin inhibits Na⁺/K⁺-ATPase activity in cardiomyocytes, resulting in increased intracellular sodium and calcium levels, with direct enhancement of contractility (APExBIO, product page).
• In vitro, Digoxin impairs chikungunya virus infection in U-2 OS, primary human synovial fibroblasts, and Vero cells, with efficacy observed at 0.01–10 μM; viral titers decrease in a dose-dependent manner (article).
• In canine models of congestive heart failure, intravenous Digoxin (1–1.2 mg) increases cardiac output and reduces right atrial pressure, with measurable effects within 30 minutes of administration (study summary).
• Digoxin is insoluble in water and ethanol but dissolves at ≥33.25 mg/mL in DMSO, enabling high-concentration stock preparation for in vitro assays (APExBIO, specs).
• Supplied by APExBIO at >98.6% purity, validated by HPLC and NMR, supporting reproducibility in research protocols (QC data).

Applications, Limits & Misconceptions

Digoxin is widely used in experimental workflows targeting cardiac contractility, arrhythmia mechanisms, and modulation of ion transport in excitable cells. Its antiviral utility is increasingly recognized, particularly in CHIKV research, where Digoxin provides a robust, dose-dependent inhibition of viral replication without overt cytotoxicity at experimental concentrations. However, its effects are context-dependent and require precise dosing and formulation.

Common Pitfalls or Misconceptions

• Not a universal antiviral: Digoxin has shown efficacy against CHIKV but may not inhibit unrelated viruses or pathogens.
• Solubility constraints: The compound is insoluble in water and ethanol; use DMSO for stock solution preparation to ensure accurate dosing.
• Species-specific effects: While results in canine models are robust, translation to other animal models or humans needs careful calibration.
• Short-term stability: Solutions are best prepared fresh; prolonged storage may compromise potency and reproducibility.
• Not a direct anticoagulant: Digoxin does not possess anticoagulant properties and should not be conflated with agents such as dabigatran etexilate (DOI:10.2146/ajhp100348).

Workflow Integration & Parameters

Preparation: Dissolve Digoxin at ≥33.25 mg/mL in DMSO for stock solutions. Avoid water or ethanol as solvents due to insolubility.

Storage: Store the solid compound at room temperature. Prepare experimental solutions just prior to use and avoid long-term storage of diluted stocks.

Dosing: In vitro studies commonly use 0.01–10 μM Digoxin. Animal model dosing, such as in canine heart failure research, employs intravenous administration at 1–1.2 mg per animal.

Quality controls: APExBIO supplies Digoxin at >98.6% purity with HPLC and NMR validation, along with a complete MSDS (specs).

For advanced troubleshooting and optimized workflow design, see the comparative protocols and troubleshooting guidance in this article, which focused on workflow enhancements for APExBIO’s Digoxin. The current article extends those guidelines by offering updated solubility and stability data relevant for translational experiments.

Conclusion & Outlook

Digoxin remains a cornerstone Na⁺/K⁺-ATPase pump inhibitor for heart failure, arrhythmia, and antiviral research. Its high purity, robust quality controls, and reproducible effects in both cardiac and infectious disease models make it indispensable for modern bench workflows. APExBIO’s Digoxin (SKU: B7684) delivers validated performance and full documentation, supporting both established and emerging research paradigms. For extended mechanism insights and translational applications beyond classic cardiac roles, see this review, which this article updates with new experimental findings and workflow recommendations.